Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Chanel Claudine de Ruiter & Thomas Rustemeyer. (2022) Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review. Psoriasis: Targets and Therapy 12, pages 99-112.
Read now
Read now
Vipawee S. Chat, Joshua Hekmatjah, Tiffany J. Sierro, Ari A. Kassardjian, Charlotte Read & April W. Armstrong. (2022) Language proficiency and biologics access: a population study of psoriasis patients in the United States. Journal of Dermatological Treatment 33:3, pages 1413-1417.
Read now
Read now
Ayman M. Mousa, Fahad A. Alhumaydhi, Ahmed A. H. Abdellatif, Waleed Al Abdulmonem, Mohammad S. AlKhowailed, Suliman A. Alsagaby, Osamah Al Rugaie, Abdullah M. Alnuqaydan, Abdullah S. M. Aljohani, Mohammad Aljasir, Ameen S. S. Alwashmi, Khaled E. A. Soliman, Mohamad Y. R. Yosof, Sayed Y. Elsheikh, Ali Yousif Babiker, Sultan A. Alsuhaibani, Ahmed M. S. Hegazy & Hanan S. Seleem. (2022) Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects. Cutaneous and Ocular Toxicology 41:1, pages 33-42.
Read now
Read now
Ciro Romano, Sergio Esposito, Roberta Ferrara & Giovanna Cuomo. (2020) Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 20:1, pages 49-62.
Read now
Read now
Articles from other publishers (16)
Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Külli Kingo, Raquel Rivera Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh & Piotr Jagiello. (2023)
Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the
STEPIn
study
. Journal of the European Academy of Dermatology and Venereology 37:5, pages 1004-1016.
Crossref
Crossref
Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt & Mark Lebwohl. (2022) Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and Therapy 13:1, pages 315-328.
Crossref
Crossref
Garyfallia STEFANOU, Georgia KOURLABA, Eirinaios VAMVAKOUSIS, Soultana KOUKOPOULOU & John YFANTOPOULOS. (2022) Patients' satisfaction, unmet needs, and treatment benefits in moderate to severe psoriasis in Greece: results from a cross-sectional survey. Italian Journal of Dermatology and Venereology 157:5.
Crossref
Crossref
M. Augustin, P.G. Sator, R. von Kiedrowski, C. Conrad, D. Rigopoulos, M. Romanelli, P.‐D. Ghislain, T. Torres, D. Ioannides, M. Aassi, B. Schulz & P. Jagiello. (2022)
Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the
SERENA
study
. Journal of the European Academy of Dermatology and Venereology 36:10, pages 1796-1804.
Crossref
Crossref
Pablo Chicharro, Mar Llamas‐Velasco, Susana Armesto, Enrique Herrera‐Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera, Pablo De la Cueva, Antonio Martorell‐Calatayud, Ferrán Ballescà, Isabel Belinchón, Gregorio Carretero, Lourdes Rodríguez, Alberto Romero‐Maté, Josep Pujol‐Montcusí, Laura Salgado, Antonio Sahuquillo‐Torralba, Pablo Coto‐Segura, Ofelia Baniandrés‐Rodríguez, Rosa Feltes, Mercè Alsina & Esteban Daudén. (2022) Fast and sustained improvement of patient‐reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy 35:8.
Crossref
Crossref
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Marina Talamonti, Matteo Megna, Massimo Raspanti, Matteo Paolinelli, Katharina Hansel, Alessandra Narcisi, Andrea Conti, Clara De Simone, Marco Adriano Chessa, Alina De Rosa, Eugenio Provenzano, Michela Ortoncelli, Chiara Moltrasio, Rosaria Fidanza, Martina Burlando, Annalisa Tonini, Francesca Maria Gaiani, Lucia Simoni, Alessandra Ori, Martina Fiocchi & Emanuela Zagni. (2021)
Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the
CANOVA
(
EffeCtiveness
of biologic
treAtmeNts
for plaque
psOriasis
in Italy: An
obserVAtional
longitudinal study of real‐life clinical practice) study
. Dermatologic Therapy 35:1.
Crossref
Crossref
N. da Silva, R. Sommer, C.‐E. Ortmann, P. Jagiello, T. Bachhuber & M. Augustin. (2021) Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. Journal of the European Academy of Dermatology and Venereology 35:11, pages 2241-2249.
Crossref
Crossref
Katherine Houghton, Dhaval Patil, Braulio Gomez & Steven R. Feldman. (2021) Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. Dermatology and Therapy 11:4, pages 1373-1384.
Crossref
Crossref
M. Augustin, E. Dauden, U. Mrowietz, M.P. Konstantinou, S. Gerdes, K. Kingo, J.C. Szepietowski, J.L. Perrot, A. Cuccia, M. Rissler, S. Gathmann, C. Sieder, R. Orsenigo, P. Jagiello & T. Bachhuber. (2020) Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. Journal of the European Academy of Dermatology and Venereology 35:2, pages 431-440.
Crossref
Crossref
M. Augustin, E. Dauden, U. Mrowietz, M.P. Konstantinou, S. Gerdes, M. Rissler, S. Gathmann, C. Sieder, D. Baeumer & R. Orsenigo. (2020) Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population. Journal of the European Academy of Dermatology and Venereology 34:11, pages 2548-2556.
Crossref
Crossref
Laura M. Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg & Richard B. Warren. (2019) Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLOS ONE 14:8, pages e0220868.
Crossref
Crossref
Warren David Raymond, Gro Østli Eilertsen, Sharanyaa Shanmugakumar & Johannes Cornelis Nossent. (2019) The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine 8:6, pages 857.
Crossref
Crossref
S. González-Parra & E. Daudén. (2019) Psoriasis and Depression: The Role of Inflammation. Actas Dermo-Sifiliográficas (English Edition) 110:1, pages 12-19.
Crossref
Crossref
S. González-Parra & E. Daudén. (2019) Psoriasis y depresión: el papel de la inflamación. Actas Dermo-Sifiliográficas 110:1, pages 12-19.
Crossref
Crossref
A. Pérez Ferriols. (2018) La importancia de medir la afectación psicológica en la psoriasis y Como tratamos a nuestros pacientes pediátricos con psoriasis. Actas Dermo-Sifiliográficas 109:8, pages 667-669.
Crossref
Crossref
Jéssica R. Silva, Beatriz Burger, Carolina M. C. Kühl, Thamiris Candreva, Mariah B. P. dos Anjos & Hosana G. Rodrigues. (2018) Wound Healing and Omega-6 Fatty Acids: From Inflammation to Repair. Mediators of Inflammation 2018, pages 1-17.
Crossref
Crossref